221 related articles for article (PubMed ID: 22576568)
1. [Anti-rheumatic effect of JAK-inhibitors].
Yamaoka K; Maeshima K; Kubo S; Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):112-7. PubMed ID: 22576568
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
3. [JAK inhibitor].
Yamaoka K; Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
5. Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.
Yamaoka K
Drug Saf; 2016 Sep; 39(9):823-40. PubMed ID: 27193610
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
8. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
9. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
10. Malignancy and Janus Kinase Inhibition.
Sivaraman P; Cohen SB
Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
[TBL] [Abstract][Full Text] [Related]
11. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Varisco PA; So A
Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
[TBL] [Abstract][Full Text] [Related]
12. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Tanaka Y
J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
[TBL] [Abstract][Full Text] [Related]
16. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
Gök K; Cengiz G; Erol K; Ozgocmen S
Acta Reumatol Port; 2017; 42(1):88-90. PubMed ID: 28371574
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
19. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors: A broadening approach in rheumatoid arthritis.
Lam S
Drugs Today (Barc); 2016 Aug; 52(8):467-469. PubMed ID: 27722215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
